Rapid hit to development candidate
A transformational small-molecule platform for rapid hit discovery and optimization against difficult-to-drug targets.
Two longstanding problems in fragment-based drug discovery
Fragment-based drug discovery (FBDD) has depended on biophysical screening to find fragment hits.
Turning those weak binders into potent, functionally active leads then takes a long, risky and costly elaboration effort.
- 1Removes dependence on biophysical screening
Breakthrough technology for functional screening of fragments combined with an AI-assisted SMART fragment library.
- 2Vastly accelerated path from fragment hit to DC
An automated, integrated chem-bio platform rapidly generates large, high-quality SAR data sets, with AI-enabled iterative data analysis and optimization.
- 3Orthosteric and allosteric
Highly effective for both orthosteric and allosteric modulators of difficult-to-drug targets.
Straight from fragments to candidates
In conventional FBDD, weakly binding fragments are slowly elaborated, gaining molecular weight on the way to potency.
The Implexsys platform takes functionally active fragments, allosteric or active-site, straight to development candidates.
From fragment to development candidate
- Screen functionallyFragments are screened for functional activity, without relying on biophysical screening.
- Generate SAR at scaleAn automated, integrated chem-bio platform rapidly produces large, high-quality SAR data sets.
- Optimize with AIAI-enabled, iterative data analysis guides each round of optimization.
- Deliver candidatesOrthosteric or allosteric development candidates against difficult-to-drug targets.
Interested in our work?
We'd like to hear from potential partners and collaborators.